“…More specifically, NMDA receptors (NMDARs) agonists have been regarded as pharmacological treatments that enhance learning, and as such, have been considered potential cognitive enhancers (see Villarejo-Rodríguez, Vale-Martínez, GuillazoBlanch, & Martí-Nicolovius, 2010). D-cycloserine (DCS) is a partial agonist at the glycine recognition site of the NMDARs and has been shown to enhance acquisition, consolidation, relearning, extinction and reconsolidation in several associative learning paradigms (Bustos, Giachero, Maldonado & Molina, 2010;Curlik & Shors, 2011;Davis, 2002;Ledgerwood, Richardson & Cranney, 2005;Lee, Milton & Everitt, 2006;Rodgers, Harvest, Hassall & Kaddour, 2011;Villarejo-Rodriguez et al, 2010). The majority of studies have focused on the role of DCS in extinction and reconsolidation, as the modulation of such processes may be useful as a treatment strategy for maladaptive memory or anxiety disorders (Davis, Ressler, Rothbaum & Richardson, 2006;Hofmann, 2007).…”